BioCentury | Feb 27, 2012
Company News

Broadvector, Vectura deal

...Vectura's Innovata Ltd. subsidiary granted Broadvector rights to IP covering a prodrug therapy for hip implant...
...Broadvector hopes to start Phase II testing next year in Europe. Details were not disclosed. Broadvector...
BioCentury | Dec 13, 2010
Financial News

Broadvector withdraws IPO

Broadvector Ltd. , Melbourne, Australia Business: Musculoskeletal, Cancer Date announced: 11/29/10 Type: IPO Note: The company withdrew its offering, noting that the minimum IPO fundraising threshold was unlikely to be reached. WIR Staff cancer Musculoskeletal...
BioCentury | Oct 4, 2010
Finance

4Q Financial Markets Preview: Watershed moment

...9/27/10 TBD Mkt (drug) Quark Pharmaceuticals Inc. (Tel Aviv) 9/24/10 Up to $20M Ph II Broadvector...
BioCentury | Sep 13, 2010
Finance

IPO watch

...purchase a share at A$0.25 for every four shares purchased. The options expire June 2013. Broadvector...
...coli and CB1954, a small molecule prodrug, to destroy the soft tissue within the joint. Broadvector...
BioCentury | Sep 13, 2010
Financial News

Broadvector proposes IPO

...purchase a share at A$0.25 for every four shares purchased. The options expire June 2013. Broadvector...
BioCentury | Sep 8, 2010
Financial News

Broadvector files for IPO

...purchase a share at A$0.25 for every four shares purchased. The options expire June 2013. Broadvector...
...the deal to close Sept. 30, with the company listing on the ASX Oct. 14. Broadvector...
Items per page:
1 - 6 of 6
BioCentury | Feb 27, 2012
Company News

Broadvector, Vectura deal

...Vectura's Innovata Ltd. subsidiary granted Broadvector rights to IP covering a prodrug therapy for hip implant...
...Broadvector hopes to start Phase II testing next year in Europe. Details were not disclosed. Broadvector...
BioCentury | Dec 13, 2010
Financial News

Broadvector withdraws IPO

Broadvector Ltd. , Melbourne, Australia Business: Musculoskeletal, Cancer Date announced: 11/29/10 Type: IPO Note: The company withdrew its offering, noting that the minimum IPO fundraising threshold was unlikely to be reached. WIR Staff cancer Musculoskeletal...
BioCentury | Oct 4, 2010
Finance

4Q Financial Markets Preview: Watershed moment

...9/27/10 TBD Mkt (drug) Quark Pharmaceuticals Inc. (Tel Aviv) 9/24/10 Up to $20M Ph II Broadvector...
BioCentury | Sep 13, 2010
Finance

IPO watch

...purchase a share at A$0.25 for every four shares purchased. The options expire June 2013. Broadvector...
...coli and CB1954, a small molecule prodrug, to destroy the soft tissue within the joint. Broadvector...
BioCentury | Sep 13, 2010
Financial News

Broadvector proposes IPO

...purchase a share at A$0.25 for every four shares purchased. The options expire June 2013. Broadvector...
BioCentury | Sep 8, 2010
Financial News

Broadvector files for IPO

...purchase a share at A$0.25 for every four shares purchased. The options expire June 2013. Broadvector...
...the deal to close Sept. 30, with the company listing on the ASX Oct. 14. Broadvector...
Items per page:
1 - 6 of 6